ArticlePharmaceuticals (Basel, Switzerland)2026
CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank.
Tehila Cohen, Estee Rebibo Demry, Allan H Young, K Kleine Schaars, Mario Juruena, Thomas G Schulze, Jaakko Kaprio, Psy-PGx Consortium, Roos van Westrhenen, Noam Shomron
Abstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Tehila CohenHuman Genetics and Computational Medicine, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Estee Rebibo DemryHuman Genetics and Computational Medicine, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Allan H YoungInstitute of Psychiatry, Psychology & Neurosciences, King's College London, London WC2R 2LS, UK.
K Kleine SchaarsOutpatient Clinic Pharmacogenetics, Parnassia Psychiatric Institute, 1062 HN Amsterdam, The Netherlands.ORCID 0009-0009-5008-244X Mario JuruenaInstitute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, 80336 Munich, Germany.ORCID 0000-0001-8558-3396 Thomas G SchulzeInstitute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Jaakko KaprioInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-3716-2455 Psy-PGx Consortium
Roos van WestrhenenOutpatient Clinic Pharmacogenetics, Parnassia Psychiatric Institute, 1062 HN Amsterdam, The Netherlands.ORCID 0000-0003-2298-9924 Noam ShomronHuman Genetics and Computational Medicine, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0001-9913-6124 Funding
European Union Horizon 2020 grant no. 945151
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
antidepressantsCYP2D6cytochrome P450depressive disorderdrug metabolismpharmacogeneticstreatment discontinuation
Identifiers
PMID42515713
PMCPMC13416362
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390